WallStSmart

DaVita HealthCare Partners Inc (DVA)vsNutex Health Inc (NUTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DaVita HealthCare Partners Inc generates 1555% more annual revenue ($14.01B vs $846.72M). NUTX leads profitability with a 21.2% profit margin vs 6.0%. NUTX trades at a lower P/E of 7.5x. DVA earns a higher WallStSmart Score of 70/100 (B).

DVA

Strong Buy

70

out of 100

Grade: B

Growth: 7.3Profit: 7.0Value: 7.3Quality: 5.5
Piotroski: 3/9Altman Z: 1.22

NUTX

Buy

63

out of 100

Grade: C+

Growth: 7.3Profit: 9.5Value: 8.3Quality: 7.5
Piotroski: 4/9Altman Z: 2.49
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DVAOvervalued (-13.0%)

Margin of Safety

-13.0%

Fair Value

$127.66

Current Price

$181.55

$53.89 premium

UndervaluedFair: $127.66Overvalued
NUTXUndervalued (+61.7%)

Margin of Safety

+61.7%

Fair Value

$269.07

Current Price

$200.24

$68.83 discount

UndervaluedFair: $269.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DVA5 strengths · Avg: 9.6/10
PEG RatioValuation
0.4510/10

Growing faster than its price suggests

Return on EquityProfitability
81.0%10/10

Every $100 of equity generates 81 in profit

EPS GrowthGrowth
55.8%10/10

Earnings expanding 55.8% YoY

Debt/EquityHealth
-14.0910/10

Conservative balance sheet, low leverage

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

NUTX5 strengths · Avg: 9.6/10
P/E RatioValuation
7.5x10/10

Attractively priced relative to earnings

Operating MarginProfitability
57.8%10/10

Strong operational efficiency at 57.8%

EPS GrowthGrowth
95.9%10/10

Earnings expanding 95.9% YoY

Return on EquityProfitability
27.8%9/10

Every $100 of equity generates 28 in profit

Profit MarginProfitability
21.2%9/10

Keeps 21 of every $100 in revenue as profit

Areas to Watch

DVA3 concerns · Avg: 2.7/10
Profit MarginProfitability
6.0%3/10

6.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Altman Z-ScoreHealth
1.222/10

Distress zone — elevated risk

NUTX2 concerns · Avg: 2.5/10
Market CapQuality
$1.32B3/10

Smaller company, higher risk/reward

Revenue GrowthGrowth
-13.6%2/10

Revenue declined 13.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : DVA

The strongest argument for DVA centers on PEG Ratio, Return on Equity, EPS Growth. PEG of 0.45 suggests the stock is reasonably priced for its growth.

Bull Case : NUTX

The strongest argument for NUTX centers on P/E Ratio, Operating Margin, EPS Growth. Profitability is solid with margins at 21.2% and operating margin at 57.8%.

Bear Case : DVA

The primary concerns for DVA are Profit Margin, Piotroski F-Score, Altman Z-Score.

Bear Case : NUTX

The primary concerns for NUTX are Market Cap, Revenue Growth.

Key Dynamics to Monitor

DVA profiles as a value stock while NUTX is a declining play — different risk/reward profiles.

NUTX carries more volatility with a beta of 2.02 — expect wider price swings.

DVA is growing revenue faster at 5.2% — sustainability is the question.

DVA generates stronger free cash flow (320M), providing more financial flexibility.

Bottom Line

DVA scores higher overall (70/100 vs 63/100). NUTX offers better value entry with a 61.7% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DaVita HealthCare Partners Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

DaVita Inc. provides kidney dialysis services through a network of outpatient dialysis centers in the United States.

Nutex Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.

Want to dig deeper into these stocks?